Application of \( ^{19} \text{F} \) NMR Spectroscopy Using a Novel \( \alpha \)-Tocopherol Derivative as a \( ^{19} \text{F} \) NMR Probe for a Pharmacokinetic Study of Lipid Nano-Emulsions in Mice

Takegami S\(^1\), Katsumi H\(^2\), Asai K\(^1\), Fujii D\(^1\), Fujimoto T\(^1\), Kawakami H\(^1\), Tokuyama T\(^1\), Konishi A\(^1\), Yamamoto A\(^2\) and Tatsuya Kitade\(^1\)

\(^1\)Department of Analytical Chemistry, Kyoto Pharmaceutical University, 5 Nakauchicho, Misasagi, Yamashina-ku, Kyoto 607-8414, Japan
\(^2\)Department of Biopharmaceutics, Kyoto Pharmaceutical University, 5 Nakauchicho, Misasagi, Yamashina-ku, Kyoto 607-8414, Japan

Abstract

Objective: The aim of our study was to demonstrate the usefulness of \( ^{19} \text{F} \) NMR magnetic resonance (NMR) spectroscopy as an analytical technique applicable for the pharmacokinetic studies of lipid nano-emulsions (LNEs) using a mixture of soybean oil, phosphatidylcholine and sodium palmimte as drug carriers.

Methods: An \( \alpha \)-tocopherol derivative, \( ^{19} \text{F}-\text{TP} \), in which a 4-(trifluoromethyl) benzoyl group was introduced to the hydroxyl group of \( \alpha \)-tocopherol was newly synthesized as a \( ^{19} \text{F} \) NMR probe. Three different LNEs containing \( ^{19} \text{F}-\text{TP} \) denoted \( ^{19} \text{F}-\text{TP}-\text{LNEs} \) (Small-LNE, Large-LNE, and polyethylene glycol-modified LNE (PEG-LNE)) were prepared by the sonication method and characterized using a dynamic light-scattering method and zeta potential analysis. The concentrations of the three \( ^{19} \text{F}-\text{TP}-\text{LNEs} \) in the blood, liver and kidney of mice were periodically evaluated based on the \( ^{19} \text{F} \) NMR signal intensity ratio of \( ^{19} \text{F}-\text{TP} \) using 0.1 mM of trifluoroethane sulfonic acid sodium salt as an internal reference.

Results: \( ^{19} \text{F}-\text{TP} \) was easily synthesized with a high yield of 96% in a one-step procedure. Small-LNE, Large-LNE and PEG-LNE had the mean particle sizes of 58, 157 and 174 nm and zeta potentials of \(-34, -53 \) and \(-32 \) mV, respectively. A single signal attributable to \( ^{19} \text{F}-\text{TP} \) in \( ^{19} \text{F}-\text{TP}-\text{LNEs} \) was observed at 15.4 ppm in the \( ^{19} \text{F} \) NMR spectra of biological samples, but was observed to decrease over time. From the change of \( ^{19} \text{F} \) NMR signal of \( ^{19} \text{F}-\text{TP} \) in biological samples, it was shown that three \( ^{19} \text{F}-\text{TP}-\text{LNEs} \) had different pharmacokinetic characteristics because of their droplet sizes and surface physical properties.

Conclusion: Based on these results, the \( ^{19} \text{F} \) NMR method was confirmed to be a convenient and useful tool for assessing the pharmacokinetics of LNEs without the need for complicated pretreatment procedures such as the deproteination of the matrix and extraction of the target compound before the \( ^{19} \text{F} \) NMR measurements.

Keywords: Lipid nano-emulsion; \( ^{19} \text{F} \) NMR; \( \alpha \)-Tocopherol; Pharmacokinetics; Particle size; Zeta potential; Drug carrier

Introduction

Investigation of the pharmacokinetics of drug carriers in the body provides valuable information for drug delivery system (DDS) research. Fluorescent probes [1] and radioisotope-labeled molecular probes [2] are generally used for this purpose. Evaluation of drug carriers distributed in the blood and organs has been performed by quantitative determination of molecular probes loaded onto drug carriers in the blood and in each organ. However, the complicated tasks of deproteination of the matrix and extraction of the target compound must be completed before analysis using high-performance liquid chromatography (HPLC) can be carried out. Moreover, the radioactive nature of the radioisotopes makes human exposure a risk and chromatography (HPLC) can be carried out. Moreover, the radioactive nature of the radioisotopes makes human exposure a risk and indicates the use of strict control measures in dedicated facilities. These complicated restrictions and pretreatment requirements interfere with the development of fast-acting, effective drug carriers.

\( ^{19} \text{F} \) nuclear magnetic resonance (NMR) spectroscopy has the potential to be a powerful tool for pharmacokinetic studies of drug carriers. The usefulness of \( ^{19} \text{F} \) NMR can be attributed to the fact that the natural abundance of the \( ^{19} \text{F} \) is 100% and its sensitivity relative to protons is approximately 83%. In addition, the \( ^{19} \text{F} \) NMR chemical shift has a range of approximately 250 ppm, which is much greater than that of the \( ^{1} \text{H} \) NMR chemical shift; that is, \( ^{19} \text{F} \) NMR signals are more sensitive to changes in the chemical environment than \( ^{1} \text{H} \) NMR signals. Because the \( ^{19} \text{F} \) nucleus is not present in natural biological substances, it is easily detectable without interfering signals even in the presence of low concentrations of \( ^{19} \text{F} \)-containing compounds [3].

Lipid nanoparticles such as lipid emulsions (LEs), liposomes, solid lipid nanoparticles and micelles have been a focus of DDS research as they are physiologically compatible, targetable, generally non-toxic and amenable to large-scale production. Compared with other carriers, LEs have many advantages including that they exhibit a higher drug solubilization capacity that are easier to process and manufacture, and are more cost effective [4,5]. LEs are frequently used for safe administration of parental nutrition in clinical settings. Because LEs are expected to act as good drug carriers because of their high lipophilicity and apolarity, which allows them to cross cell membranes, they have also been used as parenteral DDS carriers [6] for sites of...
inflammation [7], as well as the heart [8] and lymphatic system [9], because of their tendency to accumulate in these areas. Moreover, recently, LNs have been employed as carriers of anticancer agents to improve their therapeutic indices and minimize drug cytotoxicity in normal cells [10-16]. It has been recognized that only drug carriers less than 100 nm in diameter can pass through the discontinuous capillary endothelium of tumors [17]. LNs with droplet sizes on the nanometer scale are characterized as lipid nano-emulsions (LNEs). LNEs with droplet sizes of less than 100 nm show high selectivity towards tumor tissues [18,19] because they accumulate passively because of leaky tumor vasculature. This is known as the enhanced permeation and retention (EPR) effect [20,21]. In a previous study, we developed an LNE that was prepared from a lipid mixture of soybean oil (SO), phosphatidylcholine (PC), sodium palmitate (PANa) and sucrose fatty acid ester [22]. As the mean droplet size of this LNE was approximately 50 nm, it was investigated as a DDS carrier for cancer therapy [23,24].

The aim of our study was to use 19F NMR spectroscopy as an analytical technique to investigate the pharmacokinetics of LNEs. We focused on α-tocopherol (α-TP), a lipophilic vitamin with no reported adverse reactions, as the 19F NMR probe compound. In this study, we synthesized a novel 19F derivative of α-TP ([19F-TP]) for use as a 19F NMR probe by introducing a 4-(trifluoromethyl)benzoyl group to the hydroxy group of α-TP, and used 19F NMR to establish a procedure for convenient evaluation of LNE pharmacokinetics without the need for complicated pretreatment procedures.

Materials and Methods

Reagents and materials

α-TP and pyridine were purchased from Wako Pure Chemical Industries (Kyoto, Japan). 4-(Trifluoromethyl)benzoyl chloride, 4-(dimethylamino)pyridine, sodium palmitate (PANa) and bovine serum albumin (BSA, essentially fatty acid free) were purchased from Sigma-Aldrich (MO, USA). Deuterium oxide (D2O), also purchased from Sigma-Aldrich, was used as the lock signal for 19F NMR spectroscopy. Soybean oil (SO) and glycerin were purchased from Sigma-Aldrich, Inc. (St. Louis, MO, USA). Phosphatidylcholine (PC), sodium palmitate (PANa) and sucrose fatty acid ester [22]. As the mean droplet size of this LNE was approximately 50 nm, it was investigated as a DDS carrier for cancer therapy [23,24].

The mixture was emulsified by sonication using a VC-501 instrument (Tokyo Rikakikai Co., Ltd., Tokyo, Japan) for 1 h at 55°C in a thermostatic water bath. Sonication for 3 min was repeated at 3-min intervals. The 19F-TP-LNE suspensions were centrifuged at 2000 × g to eliminate sediment from the sonication tip and then stored in tightly closed, light-resistant, glass containers at room temperature under a nitrogen atmosphere. The exact 19F-TP concentrations in three 19F-TP-LNE suspensions were measured using HPLC as indicated below. Analytical samples were dissolved in methanol before injection. All measurements were carried out in triplicate. The mean and standard deviation (S.D.) of 19F-TP concentrations in three 19F-TP-LNE suspensions were 27.3 ± 1.2, 27.5 ± 0.9, and 27.1 ± 0.8 mM for Small-LNE, Large-LNE and PEG-LNE, respectively.

Characterization of 19F-TP-LNE preparations

The 19F-TP-LNE preparations were further diluted with deionized-distilled water to 1:1000 for droplet size measurement and to 1:10,000 for zeta potential measurement. The mean diameters and droplet size distributions of the 19F-TP-LNE particles were determined by dynamic light-scattering (DLS) using a Nicomp 380 analyzer (Particle Sizing Systems, Santa Barbara, CA, USA) and the 19F-TP-LNE droplet size was reported as a volume-weighted distribution. Zeta potential values were measured using a Zeeceem ZC-3000 analyzer (Microtec Co., Ltd., Chiba, Japan), based on the principle of electrophoresis.

Animals

Male specific-pathogen-free ddY mice (aged 5–6 weeks, 28-30 g) were purchased from Japan SLC Inc. (Shizuoka, Japan) and maintained under conventional housing conditions. All animal experiments were conducted in accordance with the principles and procedures outlined in the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The protocols for animal experiments were approved by the Animal Experimentation Committee of Kyoto Pharmaceutical University.

A dose of 100 μL of each of the prepared 19F-TP-LNE suspensions was injected into the mice via the tail vein. At selected intervals thereafter, the mice were lightly anesthetized, dissected and bled via the vena cava using a hypodermic needle treated with heparin, after which both the liver and kidney of the mice were excised and washed with saline.
HPLC assay

A reverse-phase HPLC method was used for analysis of 19F-TP. Quantitative determination of 19F-TP in the analytical samples prepared from the 19F-TP-LNE preparations and mouse plasma was performed by the absolute calibration method using a COSMOSIL 5C18-MS-II column (4.6×150 mm, 5 µm, Nacalai Tesque Co., Kyoto, Japan) using methanol as a mobile phase at a flow rate of 1.0 mL/min. The injection volume of the analytical samples was 20 µL and 19F-TP detection was performed using a ultraviolet detector at 280 nm. The t<sub>r</sub> value of 19F-TP was 16.7 min. This HPLC method was linear (R = 0.999) over a 19F-TP concentration range of 5-100 µM. The lower limit of quantification (LLOQ) was set at 5 µM.

19F NMR measurements

All 19F NMR spectra were measured using a UNIFITINOVA spectrometer (Agilent Technologies, Inc., Santa Clara, CA, USA) operating at 376.21 MHz without proton decoupling. The set parameters were a 3.0-µs pulse width (30° for the flip angle), a relaxation delay of 0.5 s, and an acquisition time of 0.5 s. The probe temperature was 25°C. The number of free induction decay (FID) accumulations to achieve a concentration of 0.1 mM. 19F NMR measurements were carried out using the conditions described above. 19F-TP concentrations for each organ were calculated using the calibration curve described above.

Calibration curve of 19F-TP from 19F-TP-LNE in blood

Fresh blood taken from the vena cava of male ddY mice anesthetized with ether was used without removal of the blood cells. The calibration samples were prepared by adding 300 µL of blood suspension containing various amounts of 19F-TP-LNE suspension to 240 µL of D<sub>2</sub>O and 60 µL of a 1 mM TFMS-D<sub>2</sub>O stock solution so as to achieve a concentration of 0.1 mM, and 19F NMR measurements were carried out using the conditions described above. 19F-TP concentrations were calculated using the calibration curve described above.

Calibration curve of 19F-TP from 19F-TP-LNE in liver and kidneys

First, 1 mL of lysis buffer (0.1 M Tris/HCl, 0.05% Triton X100, and 2 mM EDTA, pH 7.8) was added to 1-g samples of liver or kidney. The organ suspensions were homogenized using a Physcotron NS-360 instrument (Microtec Co. Ltd., Chiba, Japan) at 30,000 rpm for 1 min, and were used without further separation such as centrifugation or filtration. To prepare calibration samples, 300 µL of the prepared organ suspension containing various amounts of 19F-TP-LNE suspension was added to 240 µL of D<sub>2</sub>O and 60 µL of a 1 mM TFMS-D<sub>2</sub>O stock solution to achieve a concentration of ca. 0.1 mM TFMS. 19F NMR measurements were carried out in triplicate at five suitable 19F-TP concentrations under the conditions described above, and a 19F-TP calibration curve was prepared in a manner similar to that described above.

Determination of 19F-TP concentration in mouse blood using 19F-NMR

At suitable time intervals, an analytical sample was prepared by adding a 300-µL blood sample from a mouse to 240 µL of D<sub>2</sub>O and 60 µL of a 1 mM TFMS-D<sub>2</sub>O stock solution to achieve a concentration of 0.1 mM, and 19F NMR measurements were carried out using the conditions described above. 19F-TP concentrations were calculated using the calibration curve described above.

Determination of 19F-TP concentration in mouse plasma using HPLC

The blood samples from mice were centrifuged at 10,000 rpm (× 5500 g) for 5 min to give plasma samples, after which 100 µL of plasma was added to 900 µL of ultrapure water and 6 mL of ethyl acetate. After deproteinization, the mixtures were centrifuged at 3500 rpm (× 2000 g) for 10 min. Thereafter, 5 mL of the upper layer was withdrawn from the mixture and dried at 60°C. The analytical samples were prepared by adding 100 µL of methanol to the residue. The 19F-TP concentrations were measured using the HPLC experimental conditions described above.

Determination of 19F-TP concentrations in mouse liver and kidneys using 19F-NMR

At suitable time intervals, 1 mL of lysis buffer (0.1 M Tris/HCl, 0.05% Triton X100, 2 mM EDTA and pH 7.8) was added to 1-g samples of each organ, and the organ suspensions were homogenized at 30,000 rpm for 1 min. To prepare analytical samples, 300 µL of the prepared organ suspension was added to 240 µL of D<sub>2</sub>O and 60 µL of a 1 mM TFMS-D<sub>2</sub>O stock solution to achieve a final concentration of 0.1 mM. 19F NMR measurements were carried out using the conditions described above. 19F-TP concentrations for each organ were calculated using the calibration curve described above.

Results and Discussion

Chemistry

The novel compound (R)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyltridecyl)chroman-6-yl-(trifluoromethyl)benzoate (19F-TP) was synthesized with a high yield of 96% in a one-step procedure as shown in Figure 1, in which a 4-(trifluoromethyl)benzoyl group was introduced to the hydroxyl group of α-T in a widely used benzylation reaction. The structure of the final product was verified by 1H NMR spectroscopy. 1H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.37 (br d, J = 8.6 Hz, 2H), 7.79 (br d, J = 8.6 Hz, 2H), 2.62 (t, J = 7.0 Hz, 2H), 2.13 (s, 3H), 2.05 (s, 3H), 2.01 (s, 3H), 1.88-1.70 (m, 1H), 1.82 (sep, J = 7.0 Hz, 1H), 1.64-1.05 (m, 21H), 1.26 (s, 3H), 0.87 (d, J = 7.0 Hz, 9H), 0.85 (d, J = 7.0 Hz, 3H).

Characterization of 19F-TP-LNE preparations

The mean droplet sizes and zeta potential values of the three 19F-TP-LNE preparations are shown in Table 2. The mean droplet sizes of the Small-LNE, Large-LNE and PEG-LNE were 58, 157 and 174 nm, respectively. The latter two values were comparable and approximately three times larger than that of the Small-LNE. The zeta potential of the Small-LNE was –54 mV, while that of the Large-LNE was lower at –53
mV. Using the mean droplet sizes of both LNEs, the total surface area of the Small-LNE droplets was calculated to be approximately three times as large as that of the Large-LNE droplets. The amount of PANa used for the preparation of the Small-LNE was twice that used for the Large-LNE as shown in Table 1. Thus, this difference was attributable to the larger total surface area of the Small-LNE droplet compared with the Large-LNE droplet, which resulted in a smaller amount of palmitate, which contains a COO− group, per unit surface area. The zeta potential of the PEG-LNE, which had a similar droplet size to the Large-LNE, was −32 mV, which was comparable to the zeta potential of the Small-LNE. This may be the result of the fact that the surface of the PEG-LNE droplets, which was covered with a hydrophilic PEG layer, was not significantly influenced by the negative charge of the palmitate COO− group [25].

**Table 2: Particle size and zeta potential of 19F-TP-LNEs (n=3).**

| 19F-TP-LNE       | Diameter (nm) | Zeta potential (mV) |
|------------------|---------------|---------------------|
| Small-LNE        | 58 ± 3        | -34 ± 3             |
| Large-LNE        | 157 ± 4       | -53 ± 9             |
| PEG-LNE          | 174 ± 4       | -32 ± 2             |

**19F NMR spectroscopic behavior of 19F-TP and 19F-TP-LNE in the biological samples**

The LNE particles interact with various biological substances in the body after administration. If 19F-TP molecules localized at the PC/water interface of the LNE particles are pulled from the LNE particles by biological substances such as serum albumins and blood cells, this could prevent proper evaluation of the pharmacokinetics of LNE. For this reason, 19F-NMR was used to examine the behavior of 19F-TP in the LNE suspension and biological samples. Figure 2a shows the 19F NMR spectrum of the Small-LNE containing 2 mM 19F-TP in 100 mM phosphate buffer solution (pH 7.4). As shown in Figure 2a, a single sharp signal attributable to the trifluoromethyl group of 19F-TP was observed at 15.4 ppm. In contrast, the signal of 2 mM 19F-TP spiked with buffer solution containing bovine serum albumin (BSA) at a physiological concentration of 0.6 mM was shifted upfield to 14.9 ppm and considerably broadened as seen in Figure 2b. Because 19F-TP is a highly lipophilic compound, the broadened signal is considered to be derived from 19F-TP binding to BSA molecules. Meanwhile, the addition of 0.6 mM BSA to the Small-LNE buffer solution did not induce any significant changes in the chemical shift value of the 19F-TP signal, i.e., 15.4 ppm, as depicted in Figure 2c. As shown in Figures 2a, 2b and 2c, the 19F NMR signals of 19F-TP in the Small-LNE suspension were not significantly different in the absence and presence of BSA, whereas 19F-TP bound to BSA resulted in a clearly broadened signal that was shifted upfield. Thus, these results suggest that 19F-TP may be localized in the inner SO phase of the Small-LNE particles and is not present in the water phase or on the lipid monolayer/water interface of the LNE particles where 19F-TP can interact with BSA.

Figure 2d shows the 19F NMR spectrum of the Small-LNE containing 2 mM 19F-TP in a mouse blood suspension. A single sharp signal attributable to the trifluoromethyl group of 19F-TP was observed at 15.4 ppm as shown in Figure 2d. The chemical shift value of this signal was similar to the corresponding signal in Figure 2a. In contrast, as seen in Figure 2e, the signal of free 2 mM 19F-TP spiked in a blood suspension was considerably shifted downfield and slightly broadened at 16.50 ppm. The same results were also obtained for a liver suspension. This may have resulted from the single signal attributable to 19F-TP interacting with the lipid membrane of blood cells and liver tissues. As indicated by the results in Figure 2d and 2e, the magnetic environment of 19F-TP is different in the LNE particles and in the lipid membrane of biological cells, i.e., the presence of 19F-TP can be detected by examining the 19F NMR signal. To demonstrate the 19F NMR spectroscopic behavior of 19F-TP, further experiments were carried out. Figure 2f shows the 19F NMR spectrum of both free 2 mM 19F-TP and the Small-LNE containing 2 mM 19F-TP spiked in a blood suspension. As seen in Figure 2f, two single signals were separately observed at 15.4 and 16.5 ppm, and are attributable to 19F-TP in the Small-LNE and 19F-TP interacting with the lipid membrane of blood cells, respectively. The same result was also obtained for the liver suspension. The spectral results indicate that the exchange rate of 19F-TP between the two states in the LNE particles and in the blood cell membranes is slow on the 19F NMR time scale. Therefore, if the 19F-TP molecules are released from the LNE particles during blood circulation and organ accumulation, the signal at 16.5 ppm will be observed in the 19F NMR spectra for the biological samples.

**19F NMR spectra of 19F-TP-LNE in blood**

Figure 3 shows the 19F NMR spectra of 19F-TP in blood taken from the mice at 30, 60 and 360 min after the administration of the Small-LNE. A single sharp signal attributable to 19F-TP was observed at 15.4 ppm in each spectrum, but was observed to decrease over time. As sedimentation of blood cells and LNE particles was not observed in all analytical samples after the 19F NMR measurement, it was concluded that the condition of the blood samples could be maintained over long accumulation times, such as the 22 h required to improve the S/N ratio of the 19F NMR spectra in the analytical samples at 360 min after administration.

The chemical shift values obtained from the spectral data at each time are shown in Table 3. The values obtained from the 19F NMR spectra of the calibration samples used for preparation of the calibration curve are also shown in Table 3. These chemical shift values did not
change over time and were the same compared with the corresponding signals in Figure 2a and 2d. In addition, the signal attributable to the released 19F-TP interacting with the blood cells observed at 16.50 ppm in Figure 2e was not observed in the 19F NMR spectra for the analytical and calibration samples at any time. These results indicate that 19F-TP was present in the same magnetic environment over time; that is, it did not leak from the Small-LNE particles and instead, remained encapsulated in them during blood circulation and the long 19F NMR measurements. The signal intensity ratios of 19F-TP to 0.1 mM TFMS were calculated and the calibration curve was used to quantitatively determine 19F-TP. The curve showed good linearity ($R = 0.998$) over a 19F-TP concentration range of 6-2800 μM. The LLOQ of 19F-TP in blood was set at 6 μM.

### Comparison of 19F NMR and HPLC methods for examining the circulation of the 19F-TP-LNE preparations

To confirm the usefulness of 19F NMR as a convenient technique for assessing the pharmacokinetics of LNE, the 19F-TP concentrations of the Small-LNE in blood and plasma were determined using 19F NMR and traditional HPLC methods, respectively. The results are illustrated in Figure 4. There was a significant difference between the 19F-TP concentration profiles determined using 19F NMR and those determined using HPLC, and the concentrations obtained from the 19F NMR method were similar to but higher than those obtained using the HPLC method. This is probably because during the extraction of 19F-TP from the blood samples for HPLC analysis, no correction was made for any loss of 19F-TP resulting from the extraction process. While the 19F-TP concentration can be measured within approximately 20 min using the HPLC method (the $t_{1/2}$ value of 19F-TP is 16.7), complicated pretreatments such as deproteination, extraction and separation procedures are required before analysis. In contrast, using the 19F NMR method, the 19F-TP concentration can be easily obtained from intact blood samples without such complex procedures. However, there is still the need for time-consuming FID accumulations to improve the S/N ratio at lower 19F-TP concentrations; e.g., for measurement of an analytical sample at 360 min, it takes more than 22 h to acquire a 19F NMR spectrum with a S/N ratio sufficient to determine the quantity of 19F-TP. In terms of applying this procedure to the measurement of biological samples with simple pretreatments, this result demonstrates that the 19F NMR method is useful for determining the blood circulation of 19F-TP-LNE.
Organ distribution of 19F-TP-LNE preparations

19F NMR was also used to determine the amount of 19F-TP present in the livers and kidneys of mice. The calibration curve for each organ showed good linearity (R = 0.999) over a 19F-TP concentration range of 6–2400 μM. The LLOQ of 19F-TP in both organs was set at 6 μM. In addition, all of the chemical shift values of the analytical samples from both organs were unchanged compared with those in blood (Table 3). For example, the chemical shift was 15.44 ± 0.01 (ppm) in liver (N = 15), and 15.44 ± 0.01 (ppm) in kidney (N = 12), respectively. Furthermore, the signal at 16.4 ppm attributed to the released 19F-TP interacting with the lipid membrane of organ cells as shown in Figure 2e was not observed in the 19F NMR spectra for the analytical and calibration samples of both organs at any time.

The concentration profiles of the three 19F-TP-LNEs in the liver and kidney are shown in Figure 6. The profiles of the 19F-TP-LNEs in the liver correlated well with the obtained blood circulation profiles Figure 6a. As mentioned above, the Large-LNEs were eliminated from the blood just 30 min after administration. Its distribution in the liver at 30 min was approximately 14% and the concentration did not change subsequently. The uptake of both Small-LNE and PEG-LNE 30 min after administration was approximately 10%. At 60 min after administration, the Small-LNE distribution increased to 22%, compared with a distribution of approximately 15% for the PEG-LNE. This is explained by the finding that nanoparticles with diameters below approximately 70 nm will accumulate in the liver because of their penetration through the fenestrated endothelial lining [35]. The rapid increase in the Small-LNE distribution in the liver may also be attributed to the increase in LNE droplet size between 30 and 60 min after administration, which resulted in enhanced RES uptake in the Kupffer cells. The presence of PEG in the PEG-LNE resulted in a RES uptake that was lower than the distribution of the Small-LNE in the liver through a mechanism similar to that associated with the improved blood circulation of the PEG-LNE.

The distribution of the 19F-TP-LNEs in the kidneys was relatively low Figure 6b, with the Small-LNE having the highest distribution. It is likely that the Small-LNE, with a mean droplet size of approximately 60 nm, had a greater renal uptake than the other LNEs because droplets in the 50–60 nm range are susceptible to interaction with the RES in the kidneys [36]. The renal distribution of the Large-LNE was low because a large proportion had already been taken up by the liver, while the renal distribution of the PEG-LNE was low because the presence of PEG excluded the LNE from the RES. The different concentration profiles of the three 19F-TP-LNEs in the liver and kidneys show that 19F-TP is a useful 19F NMR probe for evaluating LNE distribution in various organs.

Conclusions

Differences in the droplet sizes and surface physical characteristics of the three 19F-TP-LNEs resulted in differences in their blood circulation and organ distribution characteristics. This demonstrates the validity and usefulness of 19F NMR as a convenient technique for assessing LNE pharmacokinetics. The use of 19F-TP and 19F NMR allows for convenient evaluation of LNEs and other drug carriers, and the results of this research should be useful in the development of fast-acting, effective drug carriers.

Acknowledgments

The authors thank Microtec Co. Ltd., for allowing us to use the homogenizer (Physcotron NS-360).
Figure 6: 19F-TP concentration profiles in (a) liver and (b) kidney, determined by 19F NMR after intravenous administration of (●) Small-LNE, (▲) Large-LNE, and (■) PEG-LNE in mice. Each data point represents the mean ± S.D. for three mice.

References

1. Janicj JM, Sririvas M, Kadayakkara DKK, Ahrens ET (2008) Self-delivering nanoemulsions for dual fluorene-19 MRI and fluorescence detection. J Am Chem Soc 130: 2832-2841.

2. Takino T, Konishi K, Takakura Y, Hashida M (1994) Long circulating emulsion carrier systems for highly lipophilic drugs. Biol Pharm Bull 17: 121-125.

3. Kitamura K, Omran AA, Takegami S, Kitade T, et al. (2007) 19F NMR spectroscopic characterization of the interaction of niflumic acid with human serum albumin. Anal Bioanal Chem 387: 2843-2848.

4. Lundberg BB, Mortimer B-C, Redgrave TG (1996) Submicron lipid emulsions containing amphiphatic polyethylene glycol for use as drug-carriers with prolonged circulation time. Int J Pharm 134: 119-127.

5. Fukui H, Koike T, Nakagawa T, Saheli A, Sonoke S, et al. (2003) Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nanosphere (LNS), with commercial lipid-based formulations. Int J Pharm 267: 101-112.

6. Igarashi R, Takenaga M, Matsuda T (1996) Distribution of lipid microsphere preparations. Adv Drug Deliv Rev 20: 147-154.

7. Mizushima Y, Hoshi K, Aihara H, Kurachi M (1983) Inhibition of bronchoconstriction by aerosol of a lipid emulsion containing prostaglandin E1. J Pharm Pharmacol 35: 397.

8. Kimura A, Yamaguchi H, Watanable K, Hayashi M, Awazu S (1986) Factors influencing the tissue distribution of coenzyme Q10 intravenous administered in an emulsion to rats: emulsifying agents and lipoprotein lipase activity. J Pharm Pharmacol 38: 659-662.

9. Sasaki H, Kakutani T, Hashida M, Sezaki H (1985) Absorption characteristics of the lipophilic produg of miltefosin C from injected liposomes or an emulsion. J Pharm Pharmacol 37: 461-465.

10. Kurihara A, Shibayama Y, Mizota A, Yasuno A, Ikeda M, et al. (1996) Enhanced tumor delivery and antitumor activity of paclitaxel by rhizoxin using stable lipid emulsions in mice. Pharm Res 13: 305-310.

11. Nomura T, Koreeda N, Yamashita F, Takakura Y, Hashida M (1998) Effect of particle size and charge on the disposition of lipid carriers after intratumoral injection into tissue-isolated tumors. Pharm Res 15: 128-132.

12. Maranho RC, Graziani SR, Yamaguchi N, Melo RF, Latriha MC, et al. (2002) Association of camptothecine with a lipid emulsion: in vitro, in vivo and preliminary studies in cancer patients. Cancer Chemother Pharmacol 49: 487-496.

13. Rossi J, Giasson S, Khalid MN, Delmas P, Allen C, et al. (2007) Long-circulating poly(ethylene glycol)-coated emulsions to target solid tumors. Eur J Pharm Biopharm 67: 329-338.

14. Kim SH, Kim JK, Lim SJ, Park JS, Lee MK, et al. (2008) Folate-tethered emulsion for the target delivery of retinoids to cancer cells. Eur J Pharm Biopharm 68: 618-625.

15. Zhao M, Su M, Lin X, Luo Y, He H, et al. (2010) Evaluation of docetaxel-loaded intravenous lipid emulsion: pharmacokinetics, tissue distribution, antitumor activity, safety and toxicity. Pharm Res 27: 1687-1702.

16. Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, et al. (2011) Systemic delivery of tumor suppression microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 19: 1116-1122.

17. Wisse E (1970) An electron microscopic study of the fenestrated endothelial lining of rat liver sinusoids. J Ultrastr Res 31: 125-150.

18. Seki J, Sasaki H, Doi M, Yoshikawa H, Takahashi Y, et al. (1994) Lipid nanosphere (LNS), a protein-free analogue of lipoproteins, as a novel drug carrier for parenteral administration. J Control Release 28: 352-353.

19. Miyamoto M, Hirano K, Ichikawa H, Fukumori Y, Akine Y, et al. (1999) Preparation of gadolinium-containing emulsions stabilized with phosphatidylcholine-surfactant mixtures for neutron-capture therapy. Chem Pharm Bull 47: 203-208.

20. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumor accumulation of proteins and the antitumor agent SMANCS. Cancer Res 46: 6387-6392.

21. Gabizon A, Papadopoulos D (1988) Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 85: 6949-6953.

22. Takagami S, Kitamura K, Kawada H, Matsumoto Y, Kitade T, et al. (2008) Preparation and characterization of a new lipid nano-emulsion containing two cosurfactants, sodium palmitate for droplet size reduction and sucrose palmitate for stability enhancement. Chem Pharm Bull 56: 1097-1102.

23. Takagami S, Kitamura K, Kawada H, Matsumoto Y, Yoshimura S, et al. (2013) Distribution of chloroalumium phthalocyanine in a lipid nano-emulsion as studied by second-derivative spectrophotometry. Micro Nanoysys 2: 280-285.

24. Takagami S, Takara K, Tanaka S, Yamamoto K, Hori M, et al. (2010) Characterization, in vitro cytotoxicity and cellular accumulation of paclitaxel-loaded lipid nano-emulsions. J Microencapsul 27: 453-459.

25. Hashizaki K, Itoh C, Sakai H, Yokoyama S, Taguchi H, et al. (1999) Effects of PEG chain length of phospholipid with covalently attached poly(ethylene glycol) (PEG) on the macroscopic state of liposomes. Jpn Oil Chem Soc 48: 871-876.

26. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T (1981) A pharmacokinetic analysis program, (multi) for microcomputer. J Pharmacobio-Dyn 4: 879-885.

27. Tabata Y, Ikeda Y (1988) Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. Biomaterials 9: 356-362.

28. Awasthi VD, Garcia D, Goins BA, Phillips WT (2003) Circulation and biodistribution profiles of long-circulating PEG-liposomes of various sizes in rabbits. Int J Pharm 253: 121-132.

29. Takino T, Konishi K, Takakura Y, Hashida M (1993) Controlled biodistribution of highly lipophilic drugs with various parenteral formulations. J Drug Targeting 1: 117-124.

30. Gbadamosi JK, Hunter AC, Moghimi SM (2002) PEGylation of microspheres generates a heterogeneous population of particles with differential surface characteristics and biological performance. FEBBS Lett 532: 338-344.

31. Xu F, Yuan Y, Shan X, Liu C, Tao X, et al. (2009) Long-circulation of hemoglobin-loaded polymeric nanoparticles as oxygen carriers with modulated surface charges. Int J Pharm 377: 199-206.
32. Woodle MC, Matthey KK, Newman MS, Hidayat JE, Collins LR, et al. (1992) Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes. Biochim Biophys Acta 1105: 193-200.

33. Tobio M, Gref R, Sanchez A, Langer R, Alonso MJ (1998) Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharm Res 15: 270-275.

34. Li YP, Pei YY, Zhang XY, Gu ZH, Zhou ZH, et al. (2001) PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J Control Release 71: 203-211.

35. Litzinger DC, Builing AMJ, Van Rooijen N, Huang L (1994) Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim Biophys Acta 1190: 99-107.

36. Illum L, Davis SS (1982) The targeting of drug parenterally by use of microspheres. J Parenter Sci Technol 36: 242-248.